Submitted by: Submitted by HexaReport
Views: 10
Words: 1044
Pages: 5
Category: Business and Industry
Date Submitted: 06/07/2016 01:59 AM
Hexa Reports
Market Research Reports and Insightful Company Profiles
Hemoglobinopathies Market Share, Size, Market Insights,
Trends, Market Review and Outlook, Overview And
Segment Forecasts To 2022
Global hemoglobinopathies market is expected to reach over USD 8.82 billion by 2022 according to a
new report by Grand View Research Inc. Rising prevalence of hemoglobin disorders such as sickle cell
anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market.
According to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over
70% of births. It is also reported that minimum 5% of the world population are carriers of significant
variation.
Prevalence of hemoglobinopathies is high in low-income countries such as Sub Saharan region and
South East Asia. 85% of the affected population in the U.S. and Europe has ancestral base in these
regions.
Browse Detail Report With TOC @
http://www.hexareports.com/report/hemoglobinopathies-market/details
Governments are collaborating with local institutes to undertake awareness programs for curbing the
effect of hemoglobinopathies-related mortality rate. For instance, Thalassemia Data Collection Project
and Registry and Surveillance System for Hemoglobinopathies (RuSH) projects were started in 2010 by
the Centers for Disease Control and Prevention (CDC).
Hexa Reports
Market Research Reports and Insightful Company Profiles
Low level of hygiene, insufficient healthcare infrastructure, and lesser awareness levels are some key
factors attributing to increase in base of target population in low-income regions such as South East
Asia, Mediterranean basin, and Africa.
Further key findings from the study suggest:
The market for Sickle Cell Disease (SCD) was the largest with revenue valued at over USD 2,290.0 million
in 2014. Rising prevalence of hemoglobinopathies and presence of strong product pipeline for sickle cell
anemia such as HQK-1001 and Luspatercept are...